(Reuters) – Bristol-Myers Squibb Co and Eisai Co on Thursday entered into an agreement to jointly develop and market an experimental cancer drug.
Bristol Myers will pay $650 million to Eisai and up to $2.45 billion in milestone payments.
(Reporting by Amruta Khandekar; Editing by Vinay Dwivedi)
